Skip to main content
TipRanks
Go Ultimate75% OFF

Amgen (4332) Stock Price & Analysis

0 Followers

4332 Stock Chart & Stats

HK$1,799.00HK$0.00(0.00%)
At close: 4:00 PM GMT+8
No data to display
Day’s Range
HKD 1,799.00 - HKD 1,799.00
52-Week Range
HKD 1,761.00 - HKD 1,799.00
Previous Close
HKD 1,799.00
Volume
N/A
Average Volume (3M)
0
Market Cap
HKD 1.96T
Enterprise Value
HKD 270.96B
Total Cash (Recent Filing)
HKD 13.19B
Total Debt (Recent Filing)
HKD 54.01B
Price to Earnings (P/E)
26.6
Beta
0.01
Next Earnings
Feb 09, 2027 (Est.)
Dividend Yield
4.08%

Bulls Say, Bears Say

Bulls Say

Broad Portfolio Growth

Growth is broad rather than dependent on one product, with multiple therapies delivering double-digit gains and key drivers representing most product sales. This diversification supports more durable revenue expansion, improves commercial resilience, and gives Amgen a stronger base for continued investment.

Late-stage Pipeline Strength

Positive late-stage results across oncology, respiratory disease and Sjogren’s disease strengthen the pipeline’s potential to add future growth platforms. Multiple programs reduce reliance on existing products and support portfolio renewal as therapeutic needs and competitive conditions evolve.

Strong Profitability And Cash Generation

High margins and substantial operating and free cash flow provide internal funding for research, manufacturing capacity, acquisitions and shareholder returns. This cash-generative model gives Amgen flexibility to advance its pipeline while supporting ongoing commercial and operational investment.

Bears Say

Heavy Financial Leverage

Heavy leverage leaves Amgen more exposed if earnings weaken, because interest obligations and refinancing needs can absorb cash that might otherwise support innovation or shareholder returns. The relatively small equity base also amplifies financial risk when operating performance becomes less consistent.

Uneven Cash-flow Coverage

Although absolute cash generation is strong, declining free cash flow and inconsistent coverage indicate that conversion has not been uniformly dependable. Continued volatility could constrain debt reduction, investment capacity or capital returns if operating conditions become less favorable.

Reimbursement And Adoption Barriers

Reimbursement pressure outside the U.S. could limit access and slow the commercial ramp for MariTide, while treatment-management complexity may delay broader use of T-cell engagers. These barriers could reduce the pace at which pipeline opportunities translate into durable sales.

Amgen News

4332 FAQ

What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was HK$1761.00 and its highest was HK$1799.00 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is HK$1.96T.
When is Amgen’s upcoming earnings report date?
Amgen’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 84 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Nov 03, 2026. The company reported HK$50.602 earnings per share for the quarter, beating the consensus estimate of HK$45.393 by HK$5.209.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a quarterly dividend of HK$19.766 which represents an annual dividend yield of 4.08%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 44.15.
How many shares outstanding does Amgen have?
Amgen has 540,911,500 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of HK$50.602 in its last earnings report, beating expectations of HK$45.393. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen?
Hedge funds hold Amgen shares: the largest hedge-fund position in Amgen is 1,477,706,940 shares, and hedge funds decreased their holdings by 2.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology